Rifaximin: A review of its use in reducing recurrence of overt hepatic encephalopathy episodes

Drugs

Volumn 74, Issue 18, 2014, Pages 2153-2160

  Scott, Lesley J ^a  

^a Springer ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG TOLERABILITY; HEPATIC ENCEPHALOPATHY; HUMAN; MAINTENANCE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RECURRENT DISEASE; ADULT; BIOAVAILABILITY; COMPLICATION; DRUG EFFECTS; GASTROINTESTINAL TRACT; LIVER DISEASES; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; GASTROINTESTINAL TRACT; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER DISEASES; MICROBIOTA; QUALITY OF LIFE; RIFAMYCINS; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84915749027     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0300-y     Document Type: Article

References (28)

1. Iadevaia MD, Prete AD, Cesaro C, et al. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med Evid Res. 2011;3:109-17.
2. Poh Z, Chang PEJ. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012. doi: 10.1155/2012/480309.
3. Schiano TD. Clinical management of hepatic encephalopathy. Pharmacotherapy. 2010;30(5 Pt 2):10S-5S.
4. Orr JG, et al. Resource use associated with hepatic encephalopathy in patients with liver disease [abstract no. P478]. J Hepatol. 2014;60(Supp):S228-9.
5. Prakash R, Mullen K. Mechanisms, diagnosis and mangement of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515-25.
6. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715-35.
7. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042.
8. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs. 2005;65:1697-713.
9. Salix Pharmacetuicals Inc. Xifaxan® (rifaximin): US prescribing information. 2011. http://www.salix.com/assets/pdf/prescribe-info/xifaxan-pi.pdf. Accessed 30 June 2014.
10. Norgine Ltd. Targaxan 550 mg film-coated tablets: summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/27427/SPC/TARGAXAN+550+mg+film-coated+tablets/. Accessed 30 June 2014.
11. Blandizzi C, Viscomi GC, Marzo A, et al. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res. 2014;85:39-44.
12. Viscomi GC, Campana M, Barbanti M, et al. Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm. 2008;10(8):1074-81.
13. Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Ther Adv Gastroenterol. 2011;4(3):199-206.
14. Descombe JJ, Dubourg D, Picard M. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14:51-6.
15. Golden PL, Pieniaszek HJ, Forbes WP. Steady-state rifaximin pharmacokinetics in patients with chronic liver disease and hepatic encephalopathy [abstract no. 1932]. Hepatology. 2011;54:1270A-1A.
16. Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007;27(10):1361-9.
17. Trapnell CB, Connolly M, Pentikis H. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother. 2007;41:222-8.
18. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-81.
19. Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):853-61.
20. Berni E, Bannister C, Poole C, et al. The first evaluation of the relationship between the Chronic Liver Disease Questionnaire and the EQ-5D Index in hepatic encephalopathy patients treated with rifaximin-α [poster no. PWE-154]. Meeting of the British Society of Gastroenterologists; 16-19 Jun 2014; Manchester.
21. Neff GW, Barrett AC, Bortey E, et al. Efficacy and tolerability of rifaximin in hepatitis C patients with recurrent hepatic encephalopathy [abstract no. Su1300]. Gastroenterology. 2013;144(5 Suppl):S451-2.
22. Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390-7.
23. Bannister CA, Conway P, Radwan A, et al. Patients experiencing repeated episodes of hepatic encephalopathy have increasing risk of death: a post hoc analysis of rifaximin-α open label study [abstract]. British Association for the Study of the Liver Annual Meeting; 15-17 Sep 2014; Newcastle.
24. Bannister CA, Conway P, Radwan A, et al. Patients experiencing repeated episodes of hepatic encephalopathy have increasing risk of subsequent episodes: a post hoc analysis of rifaximin-α open label study [abstract]. United European Gastroenterology Week; 18-24 Oct 2014; Vienna.
25. Neff GW, Flamm SL, Mullen KD, et al. Improved outcomes in hepatic encephalopathy using rifaximin monotherapy compared to rifaximin and lactulose combination therapy [abstract no. Su1298]. Gastroenterology. 2013;144(5 Suppl):S451.
26. Poole CD, Conway P, Nanuwa K, et al. Cost effectiveness of rifaximin-α in the reduction of recurrence of overt hepatic encephalopathy [poster no. P451]. International Liver Congress, 49th Annual Meeting of the European Association for the Study of the Liver; 9-13 Apr 2014; London.
27. Neff GW, Jones M, Jonas M, et al. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol. 2013;47(2):188-92.
28. Medicines and Healthcare products Regulatory Agency. Public Assessment Report Decentralised Procedure. Refero 550 mg film-coated tablets: procedure no. UK/H/5075/001/DC. 2012. http://www.mhra.gov.uk/SearchHelp/GoogleSearch/index.htm?q=rifaximin. Accessed 30 June 2014.